Anti Alemtuzumab (LEMTRADA) ELISA
Alemtuzumab is a fusion protein produced by recombinant DNA. It fuses the TNF receptor to the constant end of the IgG1 antibody. First, the developers isolated the DNA sequence that codes the human gene for soluble TNF receptor 2, which is a receptor that binds to tumor necrosis factor-alpha. Second, they isolated the DNA sequence that codes the human gene for the Fc end of immunoglobulin G1 (IgG1). Third, they linked the DNA for TNF receptor 2 to the DNA for IgG1 Fc. Finally, they expressed the linked DNA to produce a protein that links the protein for TNF receptor 2 to the protein for IgG1 Fc. It has U.S. F.D.A. approval to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.
Intended Use: This Anti-Alemtuzumab ELISA is a rapid and easy method for the qualitative screening of antibodies to Alemtuzumab in human serum and plasma. The Anti-Alemtuzumab is for research use only. Not for diagnostic or therapeutic procedures.
ELISA 96 wells
Publishing research using this product? Please let us know so that we can cite the reference for this product.